Literature DB >> 6207275

Serum MBP immunoreactivity and immunoglobulin level as markers of tumour type.

P A Seeldrayers, N R Hoyle, D G Thomas.   

Abstract

Forty three patients, admitted to the department of Neurological Surgery for management of central nervous system tumours, were studied pre-operatively for serum myelin basic protein immunoreactivity as a marker of central nervous system lesion and for circulating immunoglobulins and complement (C3) levels. Myelin basic protein concentration did not appear to correlate with tumour type or grade. Serum immunoglobulin levels were found to be within the normal range but the mean IgM level was significantly higher in the glioma group when compared with meningiomas.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6207275     DOI： 10.1007/bf00177900

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


  12 in total

1.  Vascular invasion by glioma cells in man: an electron microscopic study.

Authors:  P C Kung; J C Lee; L Bakay
Journal:  J Neurosurg       Date:  1969-09       Impact factor: 5.115

2.  Human astrocytoma: serum-mediated immunologic response.

Authors:  P L Kornblith; F C Dohan; W C Wood; B O Whitman
Journal:  Cancer       Date:  1974-06       Impact factor: 6.860

3.  Identification of immunoglobulin classes responsible for humoral immunity to human gliomas.

Authors:  J A Garson; E A Quindlen; P L Kornblith
Journal:  Surg Forum       Date:  1979

4.  Serum-myelin-basic-protein assay in diagnosis and prognosis of patients with head injury.

Authors:  D G Thomas; J W Palfreyman; J G Ratcliffe
Journal:  Lancet       Date:  1978-01-21       Impact factor: 79.321

5.  Serum IgM level as an index of malignancy in brain tumours.

Authors:  N Hekim; E Sayin; E Demirkaya; F Berkay
Journal:  Acta Neurochir (Wien)       Date:  1981       Impact factor: 2.216

6.  Elevation of serum immunoglobulin M (IgM) level in patients with brain tumors.

Authors:  T Tokumaru; L W Catalano
Journal:  Surg Neurol       Date:  1975-07

7.  Cytotoxic antibodies in preoperative glioma patients: a diagnostic assay.

Authors:  J P Phillips; M Sujatanond; R L Martuza; E A Quindlen; W C Wood; P L Kornblith; F C Dohan
Journal:  Acta Neurochir (Wien)       Date:  1976       Impact factor: 2.216

8.  Immunobiology of primary intracranial tumors. Part 1: studies of the cellular and humoral general immune competence of brain-tumor patients.

Authors:  M S Mahaley; W H Brooks; T L Roszman; D D Bigner; L Dudka; S Richardson
Journal:  J Neurosurg       Date:  1977-04       Impact factor: 5.115

9.  Hyaline inclusions (Pseudopsammoma bodies) in meningiomas: immunocytochemical demonstration of epithel-like secretion of secretory component and immunoglobulins A and M.

Authors:  H Budka
Journal:  Acta Neuropathol       Date:  1982       Impact factor: 17.088

10.  Immunohistochemical demonstration of IgG in meningioma.

Authors:  K Tabuchi; Y Kawakami; A Nishimoto
Journal:  Acta Neurochir (Wien)       Date:  1981       Impact factor: 2.216
View more
  1 in total

1.  Lyn mediates FIP1L1-PDGFRA signal pathway facilitating IL-5RA intracellular signal through FIP1L1-PDGFRA/JAK2/Lyn/Akt network complex in CEL.

Authors:  Bin Li; Guangsen Zhang; Cui Li; Ruijuan Li; Jingchen Lu; Zhengxi He; Quan Wang; Zhenzi Peng; Jun Wang; Yeping Dong; Chunfang Zhang; Jie Qiong Tan; Nacef Bahri; Yuexiang Wang; Chaojun Duan
Journal:  Oncotarget       Date:  2016-08-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.